Hiroaki Wakimoto

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. pmc Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors
    Hiroaki Wakimoto
    Molecular Neurosurgery Laboratory, Brain Tumor Research Center, Department of Neurosurgery, Massachusetts General Hospital, Boston, MA 02114, USA
    Cancer Res 69:3472-81. 2009
  2. pmc Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells
    Hiroaki Wakimoto
    Department of Neurosurgery, Massachusetts General Hospital, Boston, MA 02114, USA
    Neuro Oncol 14:132-44. 2012
  3. pmc Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells
    Ryuichi Kanai
    Brain Tumor Research Center, Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    J Natl Cancer Inst 104:42-55. 2012
  4. pmc Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors
    Kaoru Tamura
    Molecular Neurotherapy and Imaging Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02129, USA
    Mol Ther 21:68-77. 2013
  5. pmc Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model
    Tooba A Cheema
    Brain Tumor Research Center and Molecular Neurosurgery Laboratory, Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Proc Natl Acad Sci U S A 110:12006-11. 2013
  6. pmc A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells
    Ryuichi Kanai
    Brain Tumor Research Center, Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Clin Cancer Res 17:3686-96. 2011
  7. pmc Oncolytic herpes simplex virus counteracts the hypoxia-induced modulation of glioblastoma stem-like cells
    Donatella Sgubin
    Department of Neurosurgery, Brain Tumor Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Stem Cells Transl Med 1:322-32. 2012
  8. pmc Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects
    Jeroen A J M van de Water
    Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA
    Proc Natl Acad Sci U S A 109:16642-7. 2012
  9. pmc Effect of γ34.5 deletions on oncolytic herpes simplex virus activity in brain tumors
    Ryuichi Kanai
    Brain Tumor Research Center, Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
    J Virol 86:4420-31. 2012
  10. pmc Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts
    Tooba A Cheema
    Brain Tumor Research Center, Department of Neurosurgery, Massachusetts General Hospital, Boston, USA
    Clin Cancer Res 17:7383-93. 2011

Collaborators

Detail Information

Publications21

  1. pmc Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors
    Hiroaki Wakimoto
    Molecular Neurosurgery Laboratory, Brain Tumor Research Center, Department of Neurosurgery, Massachusetts General Hospital, Boston, MA 02114, USA
    Cancer Res 69:3472-81. 2009
    ..This is important for designing new oHSV vectors and clinical trials. Moreover, the new glioma models described in this study provide powerful tools for testing experimental therapeutics and studying invasion and angiogenesis...
  2. pmc Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells
    Hiroaki Wakimoto
    Department of Neurosurgery, Massachusetts General Hospital, Boston, MA 02114, USA
    Neuro Oncol 14:132-44. 2012
    ..These studies highlight the value of GSCs for preclinical modeling of clinically relevant, patient-specific GBM and, thus, pave the way for testing novel anti-GSC/GBM agents for personalized therapy...
  3. pmc Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells
    Ryuichi Kanai
    Brain Tumor Research Center, Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    J Natl Cancer Inst 104:42-55. 2012
    ....
  4. pmc Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors
    Kaoru Tamura
    Molecular Neurotherapy and Imaging Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02129, USA
    Mol Ther 21:68-77. 2013
    ..This study sheds new light on the mechanism by which oHSV and TRAIL function in concert to overcome therapeutic-resistance, and provides an oncolytic virus based platform to target a broad spectrum of different cancer types...
  5. pmc Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model
    Tooba A Cheema
    Brain Tumor Research Center and Molecular Neurosurgery Laboratory, Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Proc Natl Acad Sci U S A 110:12006-11. 2013
    ..Taken together, our findings demonstrate that G47Δ-mIL12 provides a multifaceted approach to targeting GSCs, tumor microenvironment, and the immune system, with resultant therapeutic benefit in a stringent glioblastoma model. ..
  6. pmc A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells
    Ryuichi Kanai
    Brain Tumor Research Center, Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Clin Cancer Res 17:3686-96. 2011
    ..One approach to enhance oHSV efficacy is by combination with other therapeutic modalities...
  7. pmc Oncolytic herpes simplex virus counteracts the hypoxia-induced modulation of glioblastoma stem-like cells
    Donatella Sgubin
    Department of Neurosurgery, Brain Tumor Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Stem Cells Transl Med 1:322-32. 2012
    ..These findings suggest that oHSV G47Δ represents a promising therapeutic strategy to target and kill GSCs, not only in normoxic areas of GBM but also within the hypoxic niche...
  8. pmc Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects
    Jeroen A J M van de Water
    Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA
    Proc Natl Acad Sci U S A 109:16642-7. 2012
    ..This study demonstrates the efficacy of SC-based EGFR targeted therapy in GBMs and provides a unique approach with clinical implications...
  9. pmc Effect of γ34.5 deletions on oncolytic herpes simplex virus activity in brain tumors
    Ryuichi Kanai
    Brain Tumor Research Center, Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
    J Virol 86:4420-31. 2012
    ..Thus, Δ68H-6 represents a new oHSV vector that is safe and effective against a variety of brain tumor models...
  10. pmc Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts
    Tooba A Cheema
    Brain Tumor Research Center, Department of Neurosurgery, Massachusetts General Hospital, Boston, USA
    Clin Cancer Res 17:7383-93. 2011
    ..We investigate a novel combinatorial approach of low-dose etoposide with an oncolytic HSV to enhance antitumor activity and limit drug toxicity...
  11. pmc Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models
    Wei Zhang
    Brain Tumor Research Center, Molecular Neurosurgery Laboratory, Department of Neurosurgery, Massachusetts General Hospital, Boston, MA, USA
    Neoplasia 15:591-9. 2013
    ..These data support the paradigm of using oHSV expressing different antiangiogenic agents and show for the first time that oHSVs expressing angiostatin and IL-12 can improve efficacy in human GBM models...
  12. doi request reprint Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma
    Zachary Barnard
    Simches Brain Tumor Research Laboratories, Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Neurosurgery 71:741-8; discussion 748. 2012
    ....
  13. pmc Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer?
    Ryuichi Kanai
    Brain Tumor Research Center, Department of Neurosurgery, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA
    Future Oncol 6:619-34. 2010
    ..In this article, we will discuss the recent progress of these combinatorial strategies between virotherapy and chemotherapy and future directions...
  14. pmc Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy
    Laura S Sasportas
    Molecular Neurotherapy and Imaging Laboratory, Department of Radiology, Massachusetts General Hospital, Harvard Medical School Boston, MA 02114, USA
    Proc Natl Acad Sci U S A 106:4822-7. 2009
    ..This study demonstrates the efficacy of diagnostic and therapeutic MSC in preclinical glioma models and forms the basis for developing stem cell-based therapies for different cancers...
  15. pmc Directed evolution of adeno-associated virus for glioma cell transduction
    Casey A Maguire
    Department of Neurology, Massachusetts General Hospital, and Neuroscience Program, Harvard Medical School, Boston, MA, USA
    J Neurooncol 96:337-47. 2010
    ....
  16. ncbi request reprint Herpes simplex virus Us3(-) mutant as oncolytic strategy and synergizes with phosphatidylinositol 3-kinase-Akt targeting molecular therapeutics
    Ta Chiang Liu
    Molecular Neurosurgery Laboratory, Brain Tumor Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Clin Cancer Res 13:5897-902. 2007
    ..We hypothesized that Us3 mutants, whose replication would be inhibited by apoptosis in normal cells, would be selective for tumor cells...
  17. doi request reprint A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models
    Tugba Bagci-Onder
    Molecular Neurotherapy and Imaging Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Cancer Res 71:154-63. 2011
    ..Our findings offer a preclinical rationale for application of mechanism-based systemically delivered antiproliferative agents and novel stem cell-based proapoptotic therapies to improve treatment of malignant gliomas...
  18. pmc Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication
    Brent J Passer
    Departments of Neurosurgery and Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Cancer Res 70:3890-5. 2010
    ..Our results indicate that ENT1 antagonists augment oHSV replication in tumor cells by increasing cellular ribonucleoside activity...
  19. pmc An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma
    Esther Rheinbay
    Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA
    Cell Rep 3:1567-79. 2013
    ..Our findings demonstrate regulatory connections among ASCL1, Wnt signaling, and collaborating TFs that are essential for the maintenance and tumorigenicity of GBM CSCs...
  20. ncbi request reprint PTEN decreases in vivo vascularization of experimental gliomas in spite of proangiogenic stimuli
    Tatsuya Abe
    Molecular Neuro oncology Laboratories, Neurosurgery Service, Center for Molecular Imaging Research, Massachusetts General Hospital, Harvard Medical School, Charlestown 02129, USA
    Cancer Res 63:2300-5. 2003
    ..Taken in combination, these results provide strong evidence of PTEN/MMAC's role in regulating glioma angiogenesis even in the presence of strong proangiogenic signals provided by constitutive EGFR activation or p53 inactivation...
  21. ncbi request reprint Intra-arterial delivery of p53-containing adenoviral vector into experimental brain tumors
    Tatsuya Abe
    Molecular Neuro oncology Laboratories, Neurosurgery Service, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, USA
    Cancer Gene Ther 9:228-35. 2002
    ..These findings indicate that intra-arterial administration of adenoviral vectors containing p53 is efficient and can result in changes in tumor size, but that long-term control of tumor growth may require multiple adenoviral treatments...